<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The <z:hpo ids='HP_0001417'>X-linked</z:hpo> deubiquitinase USP9X affects the stability and activity of numerous regulatory proteins that influence cell survival </plain></SENT>
<SENT sid="1" pm="."><plain>Recent studies suggest that decreased USP9X expression can confer a selective advantage onto developing <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> cells and thereby promotes disease progression </plain></SENT>
<SENT sid="2" pm="."><plain>To examine the effect of USP9X on the cellular responses to anticancer therapies, we derived <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> cell lines in which the USP9X locus was disrupted by homologous recombination </plain></SENT>
<SENT sid="3" pm="."><plain>The resulting USP9X-deficient <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> cells exhibited increased activation of apoptotic pathways and markedly decreased clonogenic survival in response to <z:chebi fb="0" ids="46345">5-fluorouracil</z:chebi>, a chemotherapeutic drug that is widely used for treatment of gastrointestinal <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>These unexpected results suggest that <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> with low USP9X expression might be specifically sensitized to some conventional therapeutic agents </plain></SENT>
</text></document>